Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists

American Journal of Cardiology

Volumn 97, Issue 3, 2006, Pages 426-429

  Huxtable, Lindsay M ^a   Tafreshi, Mohammad J ^a   Rakkar, Amol N S ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b Palo Verde Hematology/Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CORTICOSTEROID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; IMMUNOGLOBULIN; PREDNISONE; TIROFIBAN;

ACUTE CORONARY SYNDROME; BLEEDING; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; INCIDENCE; LABORATORY TEST; MORBIDITY; PATIENT CARE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTOPENIA;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULINS, INTRAVENOUS; MYOCARDIAL ISCHEMIA; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PREVALENCE; THROMBOCYTOPENIA; TYROSINE;

EID: 31144479574     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.08.066     Document Type: Review

References (40)

1. ReoPro Prescribing Information. Available at: http://pi.lilly.com/us/ reopro.pdf. Accessed on December 11, 2005
2. Integrilin Prescribing Information. Available at: http://www.spfiles.com/ piintegrilin.pdf. Accessed on December 11, 2005
3. Aggrastat Prescribing Information. Available at: http://www.merck.com/ product/usa/pi_circulars/a/aggrastat/aggrastat2pi.pdf. Accessed on December 11, 2005
4. A. Greinacher, P. Eichler, N. Lubenow, V. Kiefel Drug-induced and drug-dependent immune thrombocytopenias Rev Clin Exp Hematol 5.3 2001 166 201
5. M.A. Rizvi, R.S. Shah, G.E. Raskob, J.N. George Drug-induced thrombocytopenia Curr Opin Hematol 6 1999 349 353
6. R.H. Aster Drug-induced immune thrombocytopenia an overview of pathogenesis Semin Hematol 36 1999 2 6
7. M. Madan, S.D. Berkowitz Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors Am Heart J 138 1999 317 326
8. K. Peter, A. Straub, B. Kohler, M. Volkmann, M. Schwarz, W. KublerKbler, C. Bode Platelet activation as a potential mechanism of CP IIb/IIIa inhibitor-induced thrombocytopenia Am J Cardiol 84 1999 519 524
9. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
10. E.M. Antman, R.P. Giugliano, C.M. Gibson, C.H. McCabe, P. Coussement, N.S. Kleiman, A. Vahanian, A.A.J. Adgey, I. Menown, H.J. Rupprecht TIMI 14 Investigators Abciximab facilitates the rate and extent of thrombolysis results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial Circulation 99 1999 2720 2732
11. G. Montalescot, P. Barragan, O. Wittenberg, P. Ecollan, S. Elhadad, P. Villain, J.M. Boulenc, M.C. Morice, L. Maillard, M. Pansieri ADMIRAL Investigators Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction N Engl J Med 344 2001 1895 1903
12. G.W. Stone, C.L. Grines, D.A. Cox, E. Garcia, J.E. Tcheng, J.J. Griffin, G. Guagliumi, T. Stuckey, M. Turco, J.D. Carroll Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction N Engl J Med 346 2002 957 966
13. EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
14. The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study Lancet 349 1997 1429 1435
15. J.E. Tcheng, D.J. Kereiakes, A.M. Lincoff, B.S. George, N.S. Kleiman, D.C. Sane, D.B. Cines, R.E. Jordan, M.A. Mascelli, M.A. Langrall ReoPro Readministration Registry Investigators Abciximab readministration results of the ReoPro Readministration Registry Circulation 104 2001 870 875
16. The PURSUIT Trial Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes N Engl J Med 339 1998 436 443
17. The ESPRIT Investigators Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) a randomized, placebo-controlled trial Lancet 356 2000 2037 2044
18. The IMPACT-II Investigators Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II Lancet 349 1997 1422 1428
19. F.L. Paradiso-Hardy, M. Madan, S. Radhakrishnan, S. Hurden, E.A. Cohen Severe thrombocytopenia possibly related to readministration of eptifibatide Cathet Cardiovasc Intervent 54 2001 63 67
20. D.W. Bougie, P.R. Wilker, E.D. Wuitschick, B.R. Curtis, M. Malik, S. Levine, R.N. Lind, J. Pereira, R.H. Aster Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa Blood 100 2002 2071 2076
21. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction N Engl J Med 338 1998 1488 1497
22. The RESTORE Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE investigators Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis Circulation 96 1997 1445 1453
23. The PRISM study Investigators A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators N Engl J Med 338 1998 1498 1505
24. D.C. Sane, L.V. Damaraju, E.J. Topol, C.F. Cabot, M.A. Mascelli, R.A. Harrington, M.L. Simoons, R.M. Califf Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy J Am Coll Cardiol 36 2000 75 83
25. M.B. Holmes, S. Kabbani, M.W. Watkins, R.W. Battle, D.J. Schneider Abciximab-associated pseudothrombocytopenia Circulation 101 2000 938 939
26. H. Schrezenmeier, H. Muller, E. Gunsilius, H. Heimpel, E. Seifried Anticoagulant-induced pseudothrombocytopenia and psedoleucocytosis Thromb Haemost 73 1995 506 513
27. S. Moll, I. Poepping, S. Hauck, D. Gulba, R. Dietz Pseudothrombocytopenia after abciximab (ReoPro) treatment Circulation 100 1999 1460
28. R. Chun, B.A. Orser, M. Madan Platelet glycoprotein IIb/IIIa inhibitors overview and implications for the anesthesiologist Anesth Analg 95 2002 879 888
29. R.P. Giugliano Drug-induced thrombocytopenia is it a serious concern for glycoprotein IIb/IIIa receptor inhibitors? J Thromb Thrombolysis 5 1998 191 202
30. H.M. Rinder, A.A. Arbini, E.L. Snyder Optimal dosing and triggers for prophylactic use of platelet transfusions Curr Opin Hematol 6 1999 437 441
31. K.D. Heckman, G.J. Weiner, C.S. Davis, R.G. Strauss, M.P. Jones, C.P. Burns Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia 10,000/μL versus 20,000/μL J Clin Oncol 15 1997 1143 1149
32. P. Rebulla, G. Finazzi, F. Marangoni, G. Avvisati, L. Gugliotta, G. Tognoni, T. Barbui, F. Mandelli, G. Sirchia Gruppo Italiano Malatte Ematologiche Maligne dell'Adulto The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia N Engl J Med 337 1997 1870 1875
33. H. Wandt, M. Frank, G. Ehninger, C. Schneider, N. Brack, A. Daoud, I. Fackler-Schwalbe, J. Fischer, R. Gackle, T. Geer Safety and cost effectiveness of a 10 × 109/L trigger for prophylactic transfusions compared with the traditional 20 × 109/L trigger a prospective comparative trial in 105 patients with acute myeloid leukemia Blood 91 1998 3601 3606
34. J.N. George, S.H. Woolf, G.E. Raskob, J.S. Wasser, L.M. Aledort, P.J. Ballem, V.S. Blanchette, J.B. Bussel, D.B. Cines, J.G. Kelton Idiopathic thrombocytopenia purpura a practice guideline developed by explicit methods for the American Society of Hematology Blood 88 1996 3 40
35. P. Jacobs, L. Wood, D.M. Dent Results of treatment in immune thrombocytopenia Q J Med 58 1986 153 165
36. P. Jacobs, L. Wood, N. Novitzky Intravenous gammaglobulin has no advantages over oral corticosteroids as primary therapy for adults with immune thrombocytopenia a prospective randomized clinical trial Am J Med 97 1994 55 59
37. U. Pedersen-Bjergaard, M. Andersen, P.B. Hansen Drug-induced thrombocytopenia clinical data on 309 cases and the effect of corticosteroid therapy Eur J Clin Pharmacol 52 1997 183 189
38. D.J. Kereiakes, J.H. Essell, C.W. Abbottsmith, T.M. Broderick, J.P. Runyon Abciximab-associated profound thrombocytopenia therapy with immunoglobulin and platelet transfusion Am J Cardiol 78 1996 1161 1163
39. A.I. Bishara, K.O. Hagmeyer Acute profound thrombocytopenia following abciximab therapy Ann Pharmacother 34 2000 924 930
40. S.D. Berkowitz, R.A. Harrington, M.M. Rund, J.E. Tcheng Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy Circulation 95 1997 809 813